Sign in
Taking people in United StatesPhase 4

GlyNAC to Lower Long-Term Pain After Knee Replacement Surgery

Tests GlyNAC against placebo for lasting pain after knee replacement in knee osteoarthritis.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
Status
Recruiting
Phase
Phase 4
People taking part
148 people, planned
Started
6 Dec 2024
Expected to end
Mar 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GlyNAC (combination of glycine and n-acetylcysteine)
  • Placebo
Record updated
11 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with knee osteoarthritis who are having a first total knee replacement on one knee. It tests whether GlyNAC (glycine plus N-acetyl-cysteine) lowers long-lasting pain after surgery.

Age
50 years or older
Sex
All sexes
Disease stage
Medical diagnosis of osteoarthritis. Having a first (primary) total knee replacement on one knee only. Worst pain in the past 24 hours of at least 4/10.

Main reasons for not taking part

  • Existing nerve damage (neuropathy) or Complex Regional Pain Syndrome before surgery
  • Untreated thyroid or heart disease
  • Liver tests (ALT/AST) above 2x the upper normal limit, or serum creatinine >1.5 mg/dl (133 µmol/L)
  • Pregnancy
  • Leg blood vessel disease, inflammatory or autoimmune disease, cancer, or serious chronic pain outside the legs

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age 50 or older
  • Intact cognitive status and ability to provide informed consent (based on cognitive screening with the Mini Mental State Examination)
  • Ability to read and write in English sufficiently to understand and complete study questionnaires
  • Undergoing unilateral primary TKA
  • Medical diagnosis of osteoarthritis
  • Past 24 hour worst numeric rating scale (NRS) pain of at least 4/10

Who cannot take part

  • Complex Regional Pain Syndrome (CRPS) diagnosis prior to undergoing TKA
  • Untreated heart disease
  • Presence of lower extremity vascular disease, inflammatory or autoimmune disorders, or malignancy
  • Presence of current clinically significant chronic pain conditions outside of the lower extremity ( daily pain for >3 months and greater ≥3/10 in intensity or the focus of medical care)
  • Presence of other medical conditions that in the opinion of the orthopedic surgeon co-investigators would make a patient's study participation unsafe
  • Alanine transaminase/aspartate transaminase >2x upper-limit of normal range
  • serum creatinine >1.5 mg/dl
  • Diagnosis of pre-existing neuropathy
  • Untreated hypo/hyperthyroidism
  • Pregnancy

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Stephen Bruehl, PhDTaking people

About the trial

What the trial wants to find out

This is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (OS); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (glycine + N-acetyl-cysteine(GlyNAC)) reduces oxidative stress and chronic post surgical pain (CPSP) in patients undergoing total knee arthroplasty (TKA).

The 2 groups in the trial

  • GlyNAC (combination of glycine and n-acetylcysteine)Treatment being tested

    GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.

  • Placebo (alanine)Placebo, for comparison

    Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
Plain-language title
GlyNAC to Lower Long-Term Pain After Knee Replacement SurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 December 2025